CD4+ cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy

Journal of Infectious Diseases

Volumn 192, Issue 8, 2005, Pages 1407-1411

  Loutfy, Mona R ^a,e   Walmsley, Sharon L ^b   Mullin, Christopher M ^c   Perez, George ^d   Neaton, James D ^c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF MINNESOTA   (United States)

^d North Jersey Community Research Initiative   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION ANTIRETROVIRAL THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; VIREMIA; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; RANDOMIZED CONTROLLED TRIALS; VIREMIA;

EID: 25844495820     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/466537     Document Type: Article

References (15)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001; 286:2560-7.
3. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-7.
4. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998; 351: 723-4.
5. Levitz SM. Improvement in CD4+ cell counts despite persistently detectable HIV load. N Engl J Med 1998; 338:1074-5.
6. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000; 181:946-53.
7. Wood E, Hogg RS, Yip B, et al. "Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 30:159-66.
8. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401-10.
9. Piketty C, Weiss L, Thomas F, Mohamed AS, Belec L, Kazatchkine MD. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis 2001; 183:1328-35.
10. + T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy. J Infect Dis 2000; 181:1808-12.
11. Faye A, Race E, Orby V, et al. Viral fitness in patients with discordant CD4 and plasma HIV RNA evolution following protease inhibitor failure [abstract]. In: Proceedings of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). 1999:130.
12. Phenix BN, Angel JB, Mandy F, et al. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors. AIDS Res Hum Retroviruses 2000; 16:559-67.
13. Perez G, MacArthur RD, Walmsley S, et al. A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102). HIV Clin Trials 2004; 5:7-18.
14. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-65.
15. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-8.